Canopy Growth’s Summer Offensive: Tweed Relaunch and Earnings Delay Set the Stage for a Turnaround Test

Canopy Growth is hitting the Canadian retail market with a revamped Tweed brand just as it prepares to deliver a long-awaited set of financial results that will reveal the full impact of its MTL Cannabis acquisition. The timing is no accident: a holiday weekend launch on Victoria Day marks the start of a summer push aimed at clawing back shelf space from cheaper rivals, while the early-June earnings report will be the first to consolidate MTL’s operations and correct a technical accounting misstep.

The company has given its flagship Tweed line a substantial makeover. New see-through packaging, higher THC potency levels and more aggressive pricing are designed to win over price-sensitive consumers. Three new flower strains and pre-rolled joints form the core of the campaign, with a new milled format set to join the lineup later in the summer. Tweed was once the dominant name in Canada’s legal cannabis market, but steep competition eroded its presence. Now management aims to reverse that decline.

That commercial push comes against a backdrop of financial housekeeping. Canopy delayed its fourth-quarter and full-year results — originally due in May — after discovering a technical, non-cash accounting error linked to US dollar-denominated warrants that should have been classified as liabilities rather than equity. The company will also restate its financial statements for the two prior fiscal years. Crucially, the correction involves only reclassifications between equity and liabilities, plus fair-value adjustments. Revenue, margins, operating earnings, cash flow, liquidity and debt covenants are all unaffected.

Investors will be watching the June release for more than just a clean set of numbers. The integration of MTL Cannabis, acquired earlier this year, will be fully visible for the first time. Canopy estimates run-rate synergies of roughly C$10 million within 18 months and views the deal as a key lever in reaching its goal of positive adjusted EBITDA by fiscal 2027. MTL brings two Quebec production sites to the table: a 76,000-square-foot facility in Pointe-Claire and a 64,000-square-foot operation in Louiseville. The capacity will support Canopy’s push into medical cannabis, particularly for regulated export markets.

The medical segment already showed momentum in the most recent quarter. For the period ended December, net cannabis revenue came in at C$52 million. Medical sales rose 15% year-over-year to C$23 million, while recreational sales climbed 8% to the same figure. Cost controls also gained traction. The adjusted EBITDA loss narrowed to C$3 million — the lowest in the company’s history — and annualized savings reached C$29 million, with selling, general and administrative expenses declining 12%.

Should investors sell immediately? Or is it worth buying Canopy Growth?

Cash preservation remains a priority. Free cash burn slowed to C$19 million in the third quarter, and the company ended the period with C$371 million in liquidity. A recapitalisation in January pushed all debt maturities to 2031, buying crucial breathing room, though it did dilute existing shareholders.

The headwinds are well documented. Canada’s recreational market is still plagued by oversupply and margin compression. International sales have faced intermittent supply-chain disruptions in Europe. And the US remains largely off-limits to THC operations for Canadian producers, despite a 2025 executive order that rekindled speculation about federal rescheduling. Canopy holds a non-consolidated minority stake in Canopy USA, meaning any shift in US policy could unlock value, but for now the regulatory door remains mostly closed.

When Canopy finally reports before the start of trading in June, analysts will focus on three things: the revenue and margin contribution from MTL, the trajectory of gross margins — which management expects to land in the mid-to-high 30% range post-integration — and the pace of progress toward sustained profitability. The consensus revenue estimate for the fiscal fourth quarter stands at roughly C$79 million.

With a brand refresh hitting store shelves, an accounting clean-up behind it and a medical cannabis engine revving up, Canopy Growth enters the summer with perhaps its clearest strategic narrative in years. The June earnings call will reveal whether that narrative has started to produce numbers.